Merck published its Q4 and full year financial results, reporting Q4 2023 worldwide sales were US$14.6B, a 6% increase from Q4 2022. It also reported a 19% increase in sales of Keytruda® (pembrolizumab) worth US$25B across 2023. Merck explained the Keytruda® sales increase was due to increased global uptake in earlier-stage and metastatic indications.
Merck highlighted that Keytruda® received multiple FDA approvals, including Keytruda® plus Padcev®. It also reiterated that the FDA granted Priority Review of Merck and Daiichi Sankyo’s Biologics License Application for patritumab deruxtecan to treat certain patients with previously treated locally advanced or metastatic EGFR-mutated non-small cell lung cancer.